Cargando…

Individual Pharmacotherapy Management (IPM)—IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy

Antimicrobial therapy is often a life-saving medical intervention for inpatients and outpatients. Almost all medical disciplines are involved in this therapeutic procedure. Knowledge of adverse drug reactions (ADRs) and drug-drug interactions (DDIs) is important to avoid drug-related harm. Within th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolf, Ursula, Baust, Henning, Neef, Rüdiger, Steinke, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599027/ https://www.ncbi.nlm.nih.gov/pubmed/36290039 http://dx.doi.org/10.3390/antibiotics11101381

Ejemplares similares

Underdiagnosed CKD in Geriatric Trauma Patients and Potent Prevention of Renal Impairment from Polypharmacy Risks through Individual Pharmacotherapy Management (IPM-III)
por: Wolf, Ursula, et al.
Publicado: (2023)

Individual Pharmacotherapy Management (IPM) - I: a group-matched retrospective controlled clinical study on prevention of complicating delirium in the elderly trauma patients and identification of associated factors
por: Drewas, Luise, et al.
Publicado: (2022)

A Drug Safety Concept (I) to Avoid Polypharmacy Risks in Transplantation by Individual Pharmacotherapy Management in Therapeutic Drug Monitoring of Immunosuppressants
por: Wolf, Ursula
Publicado: (2023)

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023)

POLYPHARMACY VERSUS DRUG COMBINATIONS
por: Agarwal, A.K.
Publicado: (1991)

Kidney Drug Transporters in Pharmacotherapy
por: Łapczuk-Romańska, Joanna, et al.
Publicado: (2023)

Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021)

Targeting continuity of care and polypharmacy to reduce drug–drug interaction
por: Weng, Yi-An, et al.
Publicado: (2020)

Optimising pharmacotherapy in older cancer patients with polypharmacy
por: Vrijkorte, Elze, et al.
Publicado: (2019)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Performance of the RHIC IPM
por: Connolly, R, et al.
Publicado: (2001)

Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean
por: Dookeeram, Darren, et al.
Publicado: (2017)

Identification and evaluation of cases of polypharmacy and irrational pharmacotherapy in Georgia
por: Gabunia, L, et al.
Publicado: (2023)

Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review
por: Rodrigues, Maria Cristina Soares, et al.
Publicado: (2016)

Adverse drug reactions and polypharmacy in cardiac patients
por: Mugoša, Snežana, et al.
Publicado: (2012)

Polypharmacy - is there a cure for drug therapy problems?
por: Orehovački, Helena, et al.
Publicado: (2023)

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders
por: Wolff, Jan, et al.
Publicado: (2021)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Polypharmacy and potential drug–drug interactions among Greenland’s care home residents
por: Albertsen, Nadja, et al.
Publicado: (2022)

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy
por: Salamone, Sandro, et al.
Publicado: (2022)

Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients
por: Kilit, Türkan Paşalı, et al.
Publicado: (2022)

Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease
por: Miziak, Barbara, et al.
Publicado: (2021)

IPM String School and Workshop
Publicado: (2005)

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
por: Baburaj, Gayathri, et al.
Publicado: (2021)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Discrimination of approved drugs from experimental drugs by learning methods
por: Tang, Kailin, et al.
Publicado: (2011)

Adverse drug reactions in the era of multi-morbidity and polypharmacy
por: Birriel, T. Javier, et al.
Publicado: (2015)

Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2021)

The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010
por: Guthrie, Bruce, et al.
Publicado: (2015)

The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
por: Frahm, Niklas, et al.
Publicado: (2020)

Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
por: Bachmann, Paula, et al.
Publicado: (2022)

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
por: Krečak, Ivan, et al.
Publicado: (2023)

Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
por: Chen, Zhaoyan, et al.
Publicado: (2023)

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
por: King, Emily A., et al.
Publicado: (2019)

The use of mechanistic evidence in drug approval
por: Aronson, Jeffrey K., et al.
Publicado: (2018)

Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Hidden Paradoxes in Generic Drug Substitution Affecting Pharmacotherapy
por: Sapone, A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_gtsoqltpmjkq9oojk0ceqcn1bt